杨森-话题@MedSci

#杨森#

40篇内容 | 2151人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1543215, encodeId=d2f01543215bf, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=西安杨森欧洲申请将依他胺鼻腔喷雾剂用于治疗抑郁症, objectType=article, longId=150823, objectId=29c0150823ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29c0150823ef, replyNumber=0, likeNumber=89, createdTime=2018-10-13, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29c0150823ef, moduleTitle=西安杨森欧洲申请将依他胺鼻腔喷雾剂用于治疗抑郁症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29c0150823ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543214, encodeId=075515432148c, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=西安杨森宣布治疗精神分裂症的长效针剂善妥达在中国上市, objectType=article, longId=148860, objectId=fc1b1488604d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc1b1488604d, replyNumber=0, likeNumber=73, createdTime=2018-09-16, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc1b1488604d, moduleTitle=西安杨森宣布治疗精神分裂症的长效针剂善妥达在中国上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc1b1488604d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543213, encodeId=e131154321364, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=西安杨森旗下亿珂®获批适应症扩展用于一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤, objectType=article, longId=144842, objectId=fd5514484242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd5514484242, replyNumber=0, likeNumber=57, createdTime=2018-07-22, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd5514484242, moduleTitle=西安杨森旗下亿珂®获批适应症扩展用于一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd5514484242)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543212, encodeId=339e1543212ce, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=西安杨森上市国内**每月皮下注射一次抗风湿生物制剂欣普尼, objectType=article, longId=141331, objectId=b2131413318b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2131413318b, replyNumber=0, likeNumber=80, createdTime=2018-06-24, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2131413318b, moduleTitle=西安杨森上市国内**每月皮下注射一次抗风湿生物制剂欣普尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2131413318b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543211, encodeId=4d9f15432115e, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=再投25亿！杨森要在中国下一盘大棋, objectType=article, longId=139581, objectId=fffe139581d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fffe139581d0, replyNumber=0, likeNumber=110, createdTime=2018-06-02, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fffe139581d0, moduleTitle=再投25亿！杨森要在中国下一盘大棋, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fffe139581d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543210, encodeId=e3f1154321093, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=西安杨森治疗精神分裂症长效针剂善妥达®获批！, objectType=article, longId=139162, objectId=21ea139162ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21ea139162ea, replyNumber=0, likeNumber=65, createdTime=2018-05-27, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21ea139162ea, moduleTitle=西安杨森治疗精神分裂症长效针剂善妥达®获批！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21ea139162ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543209, encodeId=4cdb154320915, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=FDA警告:Keytruda和Tecentriq疗效并不优于化疗 | 杨森精神分裂症药物获批上市.., objectType=article, longId=139134, objectId=012213913486, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=012213913486, replyNumber=0, likeNumber=103, createdTime=2018-05-27, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=012213913486, moduleTitle=FDA警告:Keytruda和Tecentriq疗效并不优于化疗 | 杨森精神分裂症药物获批上市.., moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=012213913486)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543208, encodeId=4498154320898, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=杨森前列腺癌新药获FDA扩大适应症批准, objectType=article, longId=129809, objectId=5906129809eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5906129809eb, replyNumber=0, likeNumber=0, createdTime=2018-02-14, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5906129809eb, moduleTitle=杨森前列腺癌新药获FDA扩大适应症批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5906129809eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543207, encodeId=40a2154320e17, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=西安杨森抗风湿免疫病皮下注射生物制剂欣普尼®在中国获批, objectType=article, longId=125572, objectId=5dcf1255e2c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5dcf1255e2c7, replyNumber=0, likeNumber=65, createdTime=2018-01-06, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5dcf1255e2c7, moduleTitle=西安杨森抗风湿免疫病皮下注射生物制剂欣普尼®在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5dcf1255e2c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543206, encodeId=c0f91543206a0, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=N Engl J Med：疾病风险腰斩一半！杨森新药有望成一线疗法, objectType=article, longId=123301, objectId=bdfa123301f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdfa123301f1, replyNumber=0, likeNumber=55, createdTime=2017-12-15, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdfa123301f1, moduleTitle=N Engl J Med：疾病风险腰斩一半！杨森新药有望成一线疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdfa123301f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543205, encodeId=9b1c1543205c2, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=杨森修订类克®（英夫利西单抗）说明书, objectType=article, longId=121293, objectId=3270121293e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3270121293e4, replyNumber=0, likeNumber=64, createdTime=2017-11-26, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3270121293e4, moduleTitle=杨森修订类克®（英夫利西单抗）说明书, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3270121293e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543204, encodeId=e76d154320433, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=西安杨森新型血液肿瘤治疗药物亿珂(R)在中国快速上市, objectType=article, longId=120168, objectId=d63b120168b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d63b120168b5, replyNumber=0, likeNumber=54, createdTime=2017-11-17, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d63b120168b5, moduleTitle=西安杨森新型血液肿瘤治疗药物亿珂(R)在中国快速上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d63b120168b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543203, encodeId=e5c615432030f, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=西安杨森新型血液肿瘤治疗药物亿珂(R)在中国快速上市, objectType=article, longId=120164, objectId=e4e812016416, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4e812016416, replyNumber=0, likeNumber=52, createdTime=2017-11-17, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4e812016416, moduleTitle=西安杨森新型血液肿瘤治疗药物亿珂(R)在中国快速上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4e812016416)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543202, encodeId=23a5154320210, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=精神卫生日, 杨森制药, 一起来叙心, 抑郁筛查日, objectType=article, longId=115641, objectId=61ad1156417c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61ad1156417c, replyNumber=0, likeNumber=56, createdTime=2017-10-12, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61ad1156417c, moduleTitle=精神卫生日, 杨森制药, 一起来叙心, 抑郁筛查日, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61ad1156417c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543201, encodeId=04e9154320188, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=杨森银屑病新药Tremfya获批, objectType=article, longId=106037, objectId=898310603e6b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=898310603e6b, replyNumber=0, likeNumber=58, createdTime=2017-07-21, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=898310603e6b, moduleTitle=杨森银屑病新药Tremfya获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=898310603e6b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543200, encodeId=5ca61543200cd, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=强生集团旗下杨森制药召开业务回顾大会展现强劲创新医药产品线, objectType=article, longId=99454, objectId=512199454c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=512199454c1, replyNumber=0, likeNumber=60, createdTime=2017-05-25, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=512199454c1, moduleTitle=强生集团旗下杨森制药召开业务回顾大会展现强劲创新医药产品线, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=512199454c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543199, encodeId=f3ec1543199d3, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=杨森旗下耐多药结核病药物Sirturo获CHMP上市许可推荐, objectType=article, longId=28549, objectId=6d582854901, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d582854901, replyNumber=0, likeNumber=61, createdTime=2013-12-27, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d582854901, moduleTitle=杨森旗下耐多药结核病药物Sirturo获CHMP上市许可推荐, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d582854901)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543198, encodeId=d08d154319880, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=杨森向欧盟提交旗下白血病药物Ibrutinib的上市许可申请, objectType=article, longId=26204, objectId=73002620458, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73002620458, replyNumber=0, likeNumber=88, createdTime=2013-11-06, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73002620458, moduleTitle=杨森向欧盟提交旗下白血病药物Ibrutinib的上市许可申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73002620458)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543197, encodeId=2ab9154319edb, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=杨森启动ADX71149在重度抑郁症患者的II期临床试验, objectType=article, longId=6980, objectId=bc6d698058, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc6d698058, replyNumber=0, likeNumber=83, createdTime=2012-06-11, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc6d698058, moduleTitle=杨森启动ADX71149在重度抑郁症患者的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc6d698058)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543196, encodeId=3a1215431969e, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, objectTitle=西安杨森抗精神分裂新药获FDA批准, objectType=article, longId=3676, objectId=e5d536e667, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5d536e667, replyNumber=0, likeNumber=59, createdTime=2012-01-09, rootId=0, userName=陆成振, userId=421413558235, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5d536e667, moduleTitle=西安杨森抗精神分裂新药获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5d536e667)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

杨森

2020-05-29

陆成振 (审核中...)

前往app查看评论内容

#杨森#

西安杨森欧洲申请将依他胺鼻腔喷雾剂用于治疗抑郁症

2018-10-13

陆成振 (审核中...)

前往app查看评论内容

#杨森#

西安杨森宣布治疗精神分裂症的长效针剂善妥达在中国上市

2018-09-16

陆成振 (审核中...)

前往app查看评论内容

#杨森#

西安杨森旗下亿珂®获批适应症扩展用于一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤

2018-07-22

陆成振 (审核中...)

前往app查看评论内容

#杨森#

西安杨森上市国内**每月皮下注射一次抗风湿生物制剂欣普尼

2018-06-24

陆成振 (审核中...)

前往app查看评论内容

#杨森#

再投25亿！杨森要在中国下一盘大棋

2018-06-02

陆成振 (审核中...)

前往app查看评论内容

#杨森#

西安杨森治疗精神分裂症长效针剂善妥达®获批！

2018-05-27

陆成振 (审核中...)

前往app查看评论内容

#杨森#

FDA警告:Keytruda和Tecentriq疗效并不优于化疗 | 杨森精神分裂症药物获批上市..

2018-05-27

陆成振 (审核中...)

前往app查看评论内容

#杨森#

杨森前列腺癌新药获FDA扩大适应症批准

2018-02-14

陆成振 (审核中...)

前往app查看评论内容

#杨森#

西安杨森抗风湿免疫病皮下注射生物制剂欣普尼®在中国获批

2018-01-06

陆成振 (审核中...)

前往app查看评论内容

#杨森#

N Engl J Med：疾病风险腰斩一半！杨森新药有望成一线疗法

2017-12-15

陆成振 (审核中...)

前往app查看评论内容

#杨森#

杨森修订类克®（英夫利西单抗）说明书

2017-11-26

陆成振 (审核中...)

前往app查看评论内容

#杨森#

西安杨森新型血液肿瘤治疗药物亿珂(R)在中国快速上市

2017-11-17

陆成振 (审核中...)

前往app查看评论内容

#杨森#

西安杨森新型血液肿瘤治疗药物亿珂(R)在中国快速上市

2017-11-17

陆成振 (审核中...)

前往app查看评论内容

#杨森#

精神卫生日, 杨森制药, 一起来叙心, 抑郁筛查日

2017-10-12

陆成振 (审核中...)

前往app查看评论内容

#杨森#

杨森银屑病新药Tremfya获批

2017-07-21

陆成振 (审核中...)

前往app查看评论内容

#杨森#

强生集团旗下杨森制药召开业务回顾大会展现强劲创新医药产品线

2017-05-25

陆成振 (审核中...)

前往app查看评论内容

#杨森#

杨森旗下耐多药结核病药物Sirturo获CHMP上市许可推荐

2013-12-27

陆成振 (审核中...)

前往app查看评论内容

#杨森#

杨森向欧盟提交旗下白血病药物Ibrutinib的上市许可申请

2013-11-06

陆成振 (审核中...)

前往app查看评论内容

#杨森#

杨森启动ADX71149在重度抑郁症患者的II期临床试验

2012-06-11

陆成振 (审核中...)

前往app查看评论内容

#杨森#

西安杨森抗精神分裂新药获FDA批准

2012-01-09

科室
- - 订阅+
  - 更多科室
工具
服务